Reveal Your MR Imaging Potential with Elucirem™ (gadopiclenol) injection
Program Description
Introducing the Reveal Image Challenge supported by Guerbet; providing US MR imaging professionals with an opportunity to reveal their MR imaging potential with Elucirem™ (gadopiclenol) injection. See Guerbet Press Release.
Submitted MRI images using Elucirem™ will be considered, in an ‘Image of the Month’ selection campaign; leading to an ‘Image of the Year’ Reveal Event at RSNA 2023. Exciting rewards include social media exposure and publication on appliedradiology.com. Additionally, images may appear in Guerbet’s marketing and educational materials.
Participants are encouraged to showcase their imaging expertise by sharing case study information and uploading the MRI images using Elucirem™ to a secure image portal hosted by appliedradiology.com. By following the important instructions explained below and completing the Elucirem™ MRI Image Submission Form, submitted images will be reviewed by an esteemed Review Committee which includes MRI Thought Leaders and Educators, Applied Radiology Board Members, and Guerbet Associates. The image review process includes assessment of MR images that are only for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.1
1Elucirem [package insert]. Princeton, NJ: Guerbet LLC; 2022
Reward Details & Selection Process
Image of the Month
From the submitted images, an ‘Image of the Month’ will be selected by the review committee. The image of the month will be featured in the monthly Reveal Challenge social media campaign and posted on appliedradiology.com.
Submission Timelines: January 1, 2024 through October 15, 2024.
From the submitted images, an ‘Image of the Month’ will be selected by the review committee. The image of the month will be featured in the monthly Reveal Challenge social media campaign and posted on appliedradiology.com.
Submission Timelines: January 1, 2024 through October 15, 2024.
Image of the Year
One (1) image will be chosen as the Image of the Year and will be revealed at RSNA 2024. The person submitting this image will be invited to join Guerbet at their booth for a special Reveal Event. The announcement of the Image of the Year includes an interview with the winner to be published on appliedradiology.com.
One (1) image will be chosen as the Image of the Year and will be revealed at RSNA 2024. The person submitting this image will be invited to join Guerbet at their booth for a special Reveal Event. The announcement of the Image of the Year includes an interview with the winner to be published on appliedradiology.com.
Submission Requirements
To share an Elucirem™ (gadopiclenol) injection MR image, one must read and acknowledge these submission requirements.
Note: The image review process includes assessment of MR images that are only for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.1
Acknowledgement & Release
By sharing the images and case information, you confirm that you have not included identifiable patient information, you are permitted or have the right to provide such images and case information, and hereby grant Applied Radiology and Guerbet LLC* worldwide, royalty-free, sublicensable, transferrable, non-exclusive, perpetual right to use, reproduce, modify, prepare derivative works, and display or publish such images and information for any lawful purposes, whether scientific, educational or promotional.
* "Guerbet LLC" includes its respective parents, affiliates, subsidiaries, licensees, successors, and assigns and any authorized representative of any Guerbet entity (including its affiliates, subsidiaries, successor, or assigns, consultants, vendors, or contractors).
Image Submission Guidelines & Parameters
All MRI images must be anonymized. MRI images using Elucirem™ must only be for the approved FDA indications of Elucirem™ and the approved Elucirem™ dose administration.
• Formats: .jpeg, .jpg, .png
• File Size: <10 MB
• Minimum Resolution: 300 DPI
• File Size: <10 MB
• Minimum Resolution: 300 DPI
Review Committee
Jeffrey Weinreb, MD, FACR, FISMRM, FSABI
Chief, Radiology Services,
Director of MRI Services
Yale New Haven Hospital
Blake Johnson, MD, FACR
Medical Director,
Medical Scanning Consultants,
RAYUS Radiology
Ari Goldberg, MD
Diagnostic Radiology
Interventional Radiology and Diagnostic Radiology
Medical Director, Body Imaging
Medical Director, MRI
Associate Professor
Bill Faulkner, BSRT(R)(MR)(CT), FSMRT,
MRSO (MRSC™),
William Faulkner & Associates
ELUCIREM™ (gadopiclenol) injection Important Safety Information
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Risk Associated with Intrathecal Use
Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures.
ELUCIREM is not approved for intrathecal use.
Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures.
ELUCIREM is not approved for intrathecal use.
Nephrogenic Systemic Fibrosis
GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of ELUCIREM in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of ELUCIREM in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
The risk for NSF appears highest among patients with:
- Chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
- Acute kidney injury
Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
For patients at highest risk for NSF, do not exceed the recommended ELUCIREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.
Indications and Usage
ELUCIREM™ (gadopiclenol) injection is indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues), and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
Contraindications
Contraindicated in patients with history of hypersensitivity reactions to ELUCIREM.
Warnings and Precautions
- Risk Associated with Intrathecal Use: Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of ELUCIREM have not been established with intrathecal use. ELUCIREM is not approved for intrathecal use.
- Nephrogenic Systemic Fibrosis: GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of ELUCIREM among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.
- Hypersensitivity Reactions: With GBCAs, serious hypersensitivity reactions have occurred. Before ELUCIREM administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to ELUCIREM.
- Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver, and spleen). While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.
- Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent.
- Extravasation and Injection Site Reactions: Injection site reactions such as injection site pain have been reported in the clinical studies with ELUCIREM. Extravasation during ELUCIREM administration may result in tissue irritation. Ensure catheter and venous patency before the injection of ELUCIREM.
- Interference with Visualization of Lesions Visible with Non-Contrast MRI: As with any GBCA, ELUCIREM may impair the visualization of lesions seen on non-contrast MRI.
Adverse Reactions:
In clinical trials, the most frequent adverse reactions that occurred in > 0.2% of patients who received ELUCIREM included: injection site pain, headache, nausea, injection site warmth, injection site coldness, dizziness, and localized swelling.
Use in Specific Populations
- Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. There are no available data on ELUCIREM use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
- Lactation: There are no data on the presence of ELUCIREM in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is excreted in breast milk.
- Pediatric Use: The safety and effectiveness of ELUCIREM have not been established in pediatric patients younger than 2 years of age.
- Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.
- Renal Impairment: In patients with renal impairment, the exposure of gadopiclenol is increased compared to patients with normal renal function. This may increase the risk of adverse reactions such as NSF. No dose adjustment of ELUCIREM is recommended for patients with renal impairment.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see the full Prescribing Information, including the Medication Guide, for additional important safety information.
GU04230047